Search clinical trials for: ACT-541468 (hydrochloride salt)

Total 336 results

Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ACT-541468 in Healthy Young Adults and Elderly Subjects

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

A Clinical Study to Investigate the Food Effect on the Pharmacokinetics of ACT-541468 in Healthy Male Subjects

Healthy

Czechia
Idorsia Pharmaceuticals Ltd.

Completed

A Single Ascending Dose Study of ACT-541468 in Healthy Male Subjects

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Terminated

A Study in Healthy Subjects to Investigate the Safety and Tolerability of ACT- 541478 as Well as What ACT-541478 Does to the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-541478

Healthy

Germany
Idorsia Pharmaceuticals Ltd.

Completed

Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects

Healthy | Renal Insufficiency

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Mild to Moderate Obstructive Sleep Apnea

Obstructive Sleep Apnea

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Effects of Daridorexant on Nighttime Breathing in Patients With Shallow or Paused Breath During Sleep

Obstructive Sleep Apnea of Adult

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

Hepatic Impairment

Switzerland
Idorsia Pharmaceuticals Ltd.

Completed

Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder

Insomnia Disorder

United States, Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects

Healthy Subjects

Netherlands
M.D. Anderson Cancer Center
Theravance Biopharma

Completed

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

Bacteremia | Infection

United States
Idorsia Pharmaceuticals Ltd.

Completed

Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

Insomnia Disorder

United States, Germany, Spain, Hungary, Israel, Sweden
Chang Gung Memorial Hospital

Completed

Comparison of Choosing Free ALT or Free PMT for Reconstruction With Head and Neck Cancer

Head and Neck Cancer | Reconstructive Surgery

Taiwan
Sunnybrook Health Sciences Centre

Completed

Response to SLT vs. ALT in Patients Under 60 Years of Age

Glaucoma

Canada
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Drug-drug Interactions Between ACT-541468 and Ethanol in Healthy Subjects

Healthy

Netherlands
ViiV Healthcare

Completed

A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254

HIV Infections

United Kingdom
University of Calgary
Canadian Glaucoma Clinical Research Council

Completed

Randomized Prospective Study of Selective Laser Trabeculoplasty (SLT) Versus Argon Trabeculoplasty (ALT) in Patients With Pseudoexfoliation Glaucoma and Ocular Hypertension (SLT)

Ocular Hypertension | Exfoliation Syndrome

Canada
Masonic Cancer Center, University of Minnesota

Completed

IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer

FIGO Stage III and IV Ovarian Cancer | FIGO Stage III and IV Fallopian Tube Cancer | FIGO Stage III Primary Peritoneal Cancer

United States
John Sampson

Completed

Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer (ERaDICATe)

Glioblastoma

United States
Altor BioScience

Completed

QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803

Healthy

United States
Altor BioScience
National Cancer Institute (NCI)

Completed

A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Synvista Therapeutics, Inc

Completed

Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease

Coronary Artery Disease | Diabetes

United States
Aqualung Therapeutics Corp.

Not yet recruiting

Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS

Acute Respiratory Distress Syndrome (ARDS)
Masonic Cancer Center, University of Minnesota
University of Minnesota

Withdrawn

QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML

Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Treatment-Related Acute Myeloid Leukemia | High-Risk Acute Myeloid Leukemia

United States
Masonic Cancer Center, University of Minnesota

Completed

IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT

Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Myelodysplastic Syndromes (MDS) | Myeloma | Acute Lymphoblastic Leukemia (ALL) | Acute Myelogenous Leukemia (AML) | Chronic Myelogenous Leukemia (CML)

United States
Altor BioScience
National Cancer Institute (NCI)

Unknown

QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

United States
Synvista Therapeutics, Inc

Completed

The DIAMOND Study: Distensibility Improvement And Remodeling in Diastolic Heart Failure

Pulmonary Edema | Dyspnea | Heart Failure, Congestive

United States
Altimmune, Inc.

Completed

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes

United States
Altimmune, Inc.

Completed

ALT-801 in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

NASH - Nonalcoholic Steatohepatitis

Australia
Altimmune, Inc.

Completed

Efficacy and Safety of ALT-801 in the Treatment of Obesity

Obesity/Overweight

United States
Synvista Therapeutics, Inc
National Institutes of Health (NIH)

Completed

STRETCH Study: Effect of Distensibility on Endothelial-Dependent Vasoreactivity in Patients With ISH

Cardiovascular Disease

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-541468 Can Affect the Fate in the Body (Amount and Time of Presence in the Blood) of Rosuvastatin

Healthy Subjects

Czechia
Thai Red Cross AIDS Research Centre
Walter Reed Army Institute of Research (WRAIR); Henry M. Jackson Foundation...

Recruiting

Reducing HIV Persistence in Lymph Nodes by Interleukin-15 (IL-15) Receptor Super-agonist (N-803) in Acute HIV Infection

HIV/AIDS

Thailand
Alteogen, Inc.

Completed

Clinical Study of ALT-BB4 to Determine Tolerance, Safety and Pharmacokinetics in Healthy Volunteer

Health, Subjective

Korea, Republic of
Synvista Therapeutics, Inc

Terminated

Safety & Efficacy of ALT-711 (Alagebrium) in Chronic Heart Failure (BENEFICIAL)

Chronic Heart Failure

United States
Synvista Therapeutics, Inc
National Institutes of Health (NIH); National Heart and Lung Institute

Completed

The STRETCH Study: Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic Hypertension

Cardiovascular Disease

United States
Aqualung Therapeutics Corp.

Completed

First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100

ARDS, Human

Australia
Synvista Therapeutics, Inc

Completed

The BENEFICIAL Study: Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure (BENEFICIAL)

Heart Failure

Netherlands
Synvista Therapeutics, Inc

Terminated

Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I) (BREAK-DHF-I)

Diastolic Heart Failure

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects

Healthy

Netherlands
Kubota Vision Inc.
Otsuka Pharmaceutical Co., Ltd.

Completed

Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride (SEATTLE)

Geographic Atrophy

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Suspended

Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
Kubota Vision Inc.

Completed

Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy

Proliferative Diabetic Retinopathy

United States
Idorsia Pharmaceuticals Ltd.

Completed

Pharmacokinetic Interaction Between Diltiazem and ACT-541468 in Healthy Subjects

Healthy Subjects

Germany
Synvista Therapeutics, Inc

Completed

The SAPPHIRE Study (Systolic And Pulse Pressure Hemodynamic Improvement By Restoring Elasticity)

Hypertension
Altimmune, Inc.

Completed

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

Non-Alcoholic Fatty Liver Disease

United States
Altimmune, Inc.

Completed

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Non-Alcoholic Fatty Liver Disease

United States
Peter B Licht

Completed

Minimally Invasive or Open Surgery for Lung Cancer: Pain, Quality of Life and Economics. (PLEACE)

Nonsmall Cell Lung Cancer Cellular Diagnosis

Denmark
Synvista Therapeutics, Inc

Completed

The SILVER Study: Systolic Hypertension Interaction With Left Ventricular Remodeling

Hypertension | Hypertrophy, Left Ventricular

3

Subscribe